Co-ordination of cell cycle, migration and stem cell-like activity in breast cancer

Oncotarget

Volumn 5, Issue 17, 2014, Pages 7833-7842

  Lamb, Rebecca ^a   Lisanti, Michael P ^a   Clarke, Robert B ^a   Landberg, Göran ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Breast cancer; Cancer stem cells; Cell migration; Cellular proliferation

Indexed keywords

DICKKOPF 1 PROTEIN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CASE REPORT; CELL ACTIVITY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; CELL SUBPOPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; PRIMARY TUMOR; BREAST TUMOR; CELL CYCLE; CELL MOTION; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HUMANS; NEOPLASTIC STEM CELLS;

EID: 84907482174     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2312     Document Type: Article

References (22)

1. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-1717.
2. Jensen EV and Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003; 9(6):1980-1989.
3. Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108.
4. Blanco G, Holli K, Heikkinen M, Kallioniemi OP and Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer. 1990; 62(1):142-146.
5. Chambers AF, Groom AC and MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2(8):563-572.
6. Talmadge JE and Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010; 70(14):5649-5669.
7. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW and Shen CY. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene. 2001; 20(29):3814-3823.
8. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-3988.
10. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69(4):1302-1313.
11. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS and Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1(5):555-567.
12. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100(9):672-679.
13. Phillips TM, McBride WH and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24):1777-1785.
14. Mitchison TJ. The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell. 2012; 23(1):1-6.
15. Camerlingo R, Ferraro GA, De Francesco F, Romano M, Nicoletti G, Di Bonito M, Rinaldo M, D'Andrea F and Pirozzi G. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol Rep. 2014; 31(3):1127-1132.
16. D'Amico L, Patane S, Grange C, Bussolati B, Isella C, Fontani L, Godio L, Cilli M, D'Amelio P, Isaia G, Medico E, Ferracini R and Roato I. Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. Br J Cancer. 2013; 108(12):2525-2536.
17. Gangopadhyay S, Nandy A, Hor P and Mukhopadhyay A. Breast cancer stem cells: a novel therapeutic target. Clin Breast Cancer. 2013; 13(1):7-15.
18. Agur Z, Kirnasovsky OU, Vasserman G, Tencer-Hershkowicz L, Kogan Y, Harrison H, Lamb R and Clarke RB. Dickkopf1 regulates fate decision and drives breast cancer stem cells to differentiation: an experimentally supported mathematical model. PLoS One. 2011; 6(9):e24225.
19. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ and Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010; 70(2):709-718.
20. Lamb R, Ablett MP, Spence K, Landberg G, Sims AH and Clarke RB. Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One. 2013; 8(7):e67811.
21. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, Howell SJ and Clarke RB. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and-independent mechanisms. Clin Cancer Res. 2013; 19(3):643-656.
22. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G and Clarke RB. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012; 17(2):111-117.